Unresectable Locally Advanced Or Metastatic Triple-Negative Breast Cancer
BMYBristol-Myers SquibbCatalyst overview
Research summary
This catalyst tracks a Phase 3 update for Izalontamab Brengitecan (BL-B01D1) (EGFR/HER3 Bispecific ADC) in Unresectable Locally Advanced Or Metastatic Triple-Negative Breast Cancer. The expected timing is based on the latest available company guidance and may change.
02/25/26:- Ph3 BL-B01D1-307 TNBC interim analysis met dual PFS/OS endpoints; data presentation timing TBA. 05/21/26:- PANKU-Breast02 BL-B01D1-307 Ph3 data to be presented June 2, 2026. 05/31/26:- PANKU-Breast02 interim OS/PFS positive at ASCO 2026; no new safety signals.
Verification
Confirm timing and program details against the company announcement or filing.